EMERGENT BIOSOLUTIONS INC. Business Combination, Contingent Consideration, Liability, Current
EMERGENT BIOSOLUTIONS INC. (EBS) had Business Combination, Contingent Consideration, Liability, Current of $0 as of 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2025-03-04
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2024-09-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2024-06-30: Business Combination, Contingent Consideration, Liability, Current $1.70M.
- 2024-03-31: Business Combination, Contingent Consideration, Liability, Current $2.70M.
| Period end | Business Combination, Contingent Consideration, Liability, Current | Business Combination, Contingent Consideration, Liability, Current as first filed |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-04 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.70M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $2.70M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $2.70M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $2.10M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $3.60M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $3.40M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $3.40M 10-K · filed 2024-03-08 | $3.10M 10-K · filed 2023-03-01 |
| 2022-09-30 | $3.50M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.60M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $3.20M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $32.70M 10-K/A · filed 2023-12-11 | |
| 2021-09-30 | $32.60M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $33.10M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $32.70M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $23.90M 10-K · filed 2022-02-25 | |
| 2020-06-30 | $22.30M 10-Q · filed 2020-07-31 | |
| 2019-12-31 | $3.20M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $55.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $54.60M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $62.70M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $5.60M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |